AbbVie Inc. (NYSE:ABBV) had its target price hoisted by Deutsche Bank AG to $88.00 in a research report sent to investors on Thursday morning. They currently have a hold rating on the stock.

ABBV has been the subject of a number of other research reports. Zacks Investment Research cut AbbVie from a hold rating to a sell rating in a report on Tuesday, July 4th. Vetr upgraded AbbVie from a hold rating to a buy rating and set a $76.28 target price on the stock in a research report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) reaffirmed a buy rating and issued a $100.00 price target (up from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Jefferies Group LLC reaffirmed a buy rating and issued a $107.00 price target (up from $94.00) on shares of AbbVie in a research note on Friday, September 15th. Finally, BidaskClub upgraded AbbVie from a buy rating to a strong-buy rating in a research report on Wednesday, September 6th. Ten analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. AbbVie currently has an average rating of Buy and a consensus target price of $87.84.

AbbVie (ABBV) opened at 88.86 on Thursday. AbbVie has a 12 month low of $55.06 and a 12 month high of $90.95. The company has a market cap of $141.65 billion, a price-to-earnings ratio of 21.85 and a beta of 1.51. The company’s 50 day moving average is $75.76 and its 200-day moving average is $69.87.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.02. The business had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The business’s revenue was up 7.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 earnings per share. On average, analysts expect that AbbVie will post $5.52 earnings per share for the current fiscal year.

WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/deutsche-bank-ag-boosts-abbvie-inc-abbv-price-target-to-88-00/1602039.html.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a dividend of $0.64 per share. The ex-dividend date is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.88%. AbbVie’s dividend payout ratio is currently 62.90%.

In other AbbVie news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Robert A. Michael sold 6,699 shares of AbbVie stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $88.00, for a total value of $589,512.00. Following the completion of the sale, the vice president now owns 10,007 shares in the company, valued at approximately $880,616. The disclosure for this sale can be found here. Insiders sold 379,890 shares of company stock worth $27,187,817 over the last quarter. 0.23% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in ABBV. NewSquare Capital LLC raised its holdings in AbbVie by 17.3% in the 1st quarter. NewSquare Capital LLC now owns 15,866 shares of the company’s stock valued at $1,034,000 after buying an additional 2,340 shares during the period. Nisa Investment Advisors LLC lifted its position in AbbVie by 1.9% in the first quarter. Nisa Investment Advisors LLC now owns 587,875 shares of the company’s stock valued at $38,306,000 after buying an additional 10,842 shares during the last quarter. Whitnell & Co. lifted its position in AbbVie by 2.7% in the first quarter. Whitnell & Co. now owns 48,147 shares of the company’s stock valued at $3,137,000 after buying an additional 1,280 shares during the last quarter. Alta Capital Management LLC lifted its position in AbbVie by 1.1% in the first quarter. Alta Capital Management LLC now owns 26,954 shares of the company’s stock valued at $1,756,000 after buying an additional 306 shares during the last quarter. Finally, Granite Investment Advisors LLC lifted its position in AbbVie by 28.5% in the first quarter. Granite Investment Advisors LLC now owns 5,548 shares of the company’s stock valued at $362,000 after buying an additional 1,231 shares during the last quarter. 68.26% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.